Sai Parenteral’s Peer Comparison

NSE: SAIPARENT | BSE: 544742

₹473.35

₹4.10 (0.87%)

As on 04-Nov-2026 12:29IST

Market cap

₹2,081 Cr

Revenue (TTM)

₹381 Cr

P/E Ratio

126.1

P/B Ratio

4.3

Div. Yield

0 %

Edit

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	2,081	40,926	24,955	18,208	13,216
Revenue (₹ Cr)	381	10,234	2,307	2,684	1,170
Net Profit (₹ Cr)	14.26	1,092.67	452.55	669.74	279.64
Net Margin (%)	3.65	10.67	19.31	24.24	22.94
RoE (%)	4.88	21.65	23.18	19.79	13.92
Price to Earnings	126.07	37.43	55.14	27.19	46.79
Price-To-Book	4.27	7.66	12.30	5.01	3.18

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	381.00	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	390.93	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	343.65	7,457.80	1,448.49	1,754.55	686.95
EBITDA	37.35	1,745.74	574.50	797.28	367.94
Depreciation	16.85	415.05	91.74	75.36	74.46
EBIT	20.50	1,330.70	482.76	721.93	293.48
Interest	18.51	143.67	23.95	5.37	0.82
Other Income	9.94	131.47	30.17	60.41	52.36
Exceptional Items	--	-31.35	--	-25.66	-3.28
Profit before Tax	11.93	1,287.14	488.98	751.31	344.65
Provision for Tax	-2.33	345.87	124.98	186.83	85.42
Profit after Tax	14.26	941.27	364.00	564.48	259.23

Liabilities (₹ Cr)

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	490.77	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	4.35	26.64	--	--	-1.92
Non-Current Liabilities	348.36	584.19	345.47	142.73	47.58
Current Liabilities	572.63	3,912.24	710.20	682.24	169.08
Total Liabilities	1,424.23	9,514.48	2,930.14	4,157.10	2,231.79

Assets (₹ Cr)

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	594.13	3,861.01	1,447.01	1,333.54	981.68
Current Assets	821.98	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	1,424.23	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	319.49	1,204.08	196.61	0.00	0.00
Net Current Assets	249.35	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	5.67	258.92	13.18	4.82	3.76

Cashflow (₹ Cr)

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	93.05	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-273.83	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	595.65	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	414.88	93.92	-56.08	-69.08	11.28

Ratios

Profitability Ratios

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	6.10	25.25	27.50	24.61	18.04
ROE (%)	4.88	20.09	21.43	18.41	13.54
ROA (%)	1.69	10.70	14.25	14.27	12.15
EBIT Margin (%)	12.41	20.40	29.89	33.61	39.84
Net Margin (%)	3.65	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	8.17	14.44	22.53	24.81	31.63

Growth Ratios

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	133.59	16.56	36.98	6.91	-12.10
EBIT Growth (%)	18.14	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	-1.16	33.05	39.94	16.24	-30.25
EPS Growth (%)	-29.98	35.59	39.94	16.05	-29.80
Book Value Growth (%)	423.95	11.36	22.95	18.43	11.27

Valuation Ratios

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	0.00	32.73	42.34	21.18	40.73
Price / Book Value	0.00	6.13	8.23	3.60	5.27
Dividend Yield (%)	--	0.23	0.28	0.51	0.74
EV/EBITDA	-1.59	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	0.00	30,257.56	15,412.11	11,956.86	10,627.92

Solvency Ratios

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.65	0.24	0.10	0.00	0.00
Short term debt to equity ratio	0.45	0.16	--	--	--
Current Ratio	1.44	1.43	2.09	4.14	7.39
Quick Ratio	1.14	0.82	1.37	3.12	5.46
Interest Coverage	1.64	9.96	21.42	140.86	419.57

Operating Efficiency Ratios

	Sai Parenteral’s	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	47.52	27.84	26.76	42.05	43.63
Asset Turnover	0.45	1.07	0.79	0.65	0.49
Receivable days	147.34	88.68	77.32	144.58	169.86
Inventory Days	106.77	84.11	80.83	96.67	97.92
Payable days	155.63	176.65	125.94	135.45	159.68
Cash Conversion Cycle	98.48	-3.86	32.22	105.80	108.11